Imaavy
Imaavy ingredients
| Active ingredient | Strength |
|---|---|
| Nipocalimab | 185 mg/mL |
What Imaavy is used for
The FDA lists the approved uses on the official label (below). In the EU, nipocalimab is approved as Imaavy for:
Imaavy is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult and adolescent patients aged 12 years of age and older who are anti‑acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Imaavy
- Generic name
- Nipocalimab-aahu
- Made by
- Janssen Biotech, Inc.
- Forms
- Injection, Solution, Concentrate
- Given
- Intravenous
- FDA approval
- Biologic licence (BLA) BLA761430
- On the US market since
- 2025
Official information
- Imaavy prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Nipocalimab-aahu)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Imaavy?
Imaavy (Nipocalimab-aahu) is a specialist medicine made by Janssen Biotech, Inc., approved by the US FDA.
What are the ingredients of Imaavy?
Imaavy contains Nipocalimab (185 mg/mL).
Is Imaavy approved in Europe?
The same active substance is approved in the EU as Imaavy.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA